Controlling the Focus of a Camera Using Focus Statistics

Apparatus for controlling the focus of a camera arranged to capture a sequence of frames, includes an image processor configured to: form an image characteristic for a plurality of blocks of a first frame, each block comprising one or more pixels of the first frame; and calculate an image parameter for each block by combining the image characteristics of blocks lying within a predefined zone relative to that block; and a focus controller configured to derive a measure of focus for a selected frame area of the first frame by identifying a set of blocks whose respective predefined zones, when combined, substantially represent the selected frame area, and forming a measure of focus for the selected frame area by so combining the image parameters of the set of blocks; wherein the focus controller is configured to generate a signal for controlling camera focus in dependence on the measure of focus formed for the selected frame area of the first frame.

Controlling the Focus of a Camera Using Focus Statistics

Apparatus for controlling the focus of a camera arranged to capture a sequence of frames, includes an image processor configured to: form an image characteristic for a plurality of blocks of a first frame, each block comprising one or more pixels of the first frame; and calculate an image parameter for each block by combining the image characteristics of blocks lying within a predefined zone relative to that block; and a focus controller configured to derive a measure of focus for a selected frame area of the first frame by identifying a set of blocks whose respective predefined zones, when combined, substantially represent the selected frame area, and forming a measure of focus for the selected frame area by so combining the image parameters of the set of blocks; wherein the focus controller is configured to generate a signal for controlling camera focus in dependence on the measure of focus formed for the selected frame area of the first frame.

DRIED IMPLANT COMPOSITION AND INJECTABLE AQUEOUS IMPLANT FORMULATION

A dried implant composition for preparing an injectable aqueous implant formulation that is extrudable through a tapering system and a gauge 18 cannula, including a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 μm and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve; an injectable aqueous implant formulation for use in a method of oral tissue regeneration, wherein the injectable aqueous implant formulation is obtainable by hydration and homogeneous mixing; a process for preparing the injectable aqueous implant formulation; and a kit for preparing the injectable aqueous implant formulation for use in oral tissue regeneration. 1. A method of treating a subject with an injectable aqueous implant formulation , wherein the subject is in need of oral tissue regeneration , comprising implanting the injectable aqueous implant formulation of in an oral cavity of the subject by extruding the injectable aqueous implant formulation of through a tapering system and a gauge 18 cannula (having an inner diameter of 0.838 mm) positioned in the implantation site.2. The method of claim 1 , further comprising claim 1 , before said implanting:a) providing a dried implant composition that consists essentially of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 μm and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of hydroxyapatite to collagen is from 1.8 to 4.5; andb) rehydrating 25-45 w/w % of the dried implant composition in a pharmaceutically acceptable aqueous vehicle and mixing to form the injectable rehydrated aqueous implant formulation.3. The method of claim 2 , wherein the dried implant composition has a w/w ratio of hydroxyapatite to collagen of from 2.5 to 4.2.4. The method of claim 2 , wherein in the dried implant composition the hydroxyapatite ...

Controlling the Focus of a Camera Using Focus Statistics

Apparatus for controlling the focus of a camera arranged to capture a sequence of frames, includes an image processor configured to: form an image characteristic for a plurality of blocks of a first frame, each block comprising one or more pixels of the first frame; and calculate an image parameter for each block by combining the image characteristics of blocks lying within a predefined zone relative to that block; and a focus controller configured to derive a measure of focus for a selected frame area of the first frame by identifying a set of blocks whose respective predefined zones, when combined, substantially represent the selected frame area, and forming a measure of focus for the selected frame area by so combining the image parameters of the set of blocks; wherein the focus controller is configured to generate a signal for controlling camera focus in dependence on the measure of focus formed for the selected frame area of the first frame.

DRIED IMPLANT COMPOSITION AND INJECTABLE AQUEOUS IMPLANT FORMULATION

A dried implant composition for preparing an injectable aqueous implant formulation that is extrudable through a tapering system and a gauge 18 cannula, including a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 μm and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve; an injectable aqueous implant formulation, wherein the injectable aqueous implant formulation is obtainable by hydration and homogeneous mixing; a process for preparing the injectable aqueous implant formulation; and a kit for preparing the injectable aqueous implant formulation. 110-. (canceled)11. A syringe containing a dried mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 μm and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve , whereby the w/w ratio of the nanocrystalline hydroxyapatite particles to the naturally crosslinked fibrous collagen material is from 1.8 to 4.5.12. An injectable aqueous implant formulation , wherein the injectable aqueous implant formulation comprises 25-45 w/w % of a dried implant composition consisting essentially of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 μm and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve , whereby the w/w ratio of hydroxyapatite to collagen is from 1.8 to 4.5 , homogenized in a pharmaceutically acceptable aqueous vehicle , wherein the injectable aqueous implant formulation having properties such that it is extrudable through a tapering system and an 18 gauge (0.838 mm inner diameter) 25.4 mm long cannula with a force not exceeding 60 N.13. The injectable aqueous implant formulation of claim 12 , wherein the formulation comprises 30-40 w/w % of the dried implant and having properties such that it is extrudable through a tapering system ...

INJECTABLE AQUEOUS IMPLANT FORMULATION CONTAINING ASCORBIC ACID

An injectable aqueous implant formulation, and processes for making and using the formulation, wherein the injectable aqueous implant formulation has been sterilized by gamma-ray or X-ray-irradiation and can be extruded through a tapering system and an 18 gauge (0.838 mm inner diameter) 25.4 mm long cannula with a force not exceeding 60 N, which comprises 25-45 w/w % of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 μm as determined by sieving and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 1.8 to 4.5, which contains at least 0.05% (w/w) ascorbic acid. 1. An injectable aqueous implant formulation which has been sterilized by gamma-ray or X-ray-irradiation and which comprises 25-45 w/w % of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 μm as determined by sieving and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve , whereby the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 1.8 to 4.5 and the injectable aqueous formulation comprises 0.1-1% (w/w) ascorbic acid.2. The injectable aqueous implant formulation of claim 1 , comprising 30-40 w/w % of the mixture of nanocrystalline hydroxyapatite particles.3. The injectable aqueous implant formulation of claim 1 , comprising 29.50 to 30.50 w/w % of the mixture of nanocrystalline hydroxyapatite particles.4. (canceled)5. The injectable aqueous implant formulation of claim 1 , comprising 0.2-0.5% (w/w) ascorbic acid.6. The injectable aqueous implant formulation of claim 1 , wherein the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 2.5 to 4.2.7. The injectable aqueous implant formulation of claim 1 , wherein the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 2.5 to 4.0.8. The injectable ...

Methods and apparatus for data analysis

A method and apparatus for data analysis according to various aspects of the present invention is configured to automatically identify a characteristic of a fabrication process for components based on test data for the components.

Use of promoters of filamentous fungi

De nouveaux vecteurs sont utilisés dans des champignons filamenteux tels que l'Aspergillus sp., en particulier, permettant l'insertion de régions de codage de protéine pour obtenir l'expression ou l'expression suivie de la sécrétion de la protéine codée à partir de l'hôte. Des séquences peptides signaux et des séquences d'activeurs utiles à cet effet sont décrites ainsi que le sont des vecteurs d'expression contenant des régions de codage natives ou étrangères à l'hôte du champignon. Selon l'invention, un champignon filamenteux tel que l'Aspergillus peut être doté de régions de codage étrangères ou naturelles associées à des séquences d'activeurs naturelles ou étrangères et éventuellement des séquences peptides signaux qui peuvent être utilisées pour commander l'expression et/ou la sécrétion des protéines codées par ces régions de codage. New vectors are used in filamentous fungi such as Aspergillus sp., In particular, allowing the insertion of protein coding regions to obtain expression or expression followed by secretion of the protein encoded from the host. Signal peptide sequences and activator sequences useful for this purpose are described as are expression vectors containing coding regions native or foreign to the host of the fungus. According to the invention, a filamentous fungus such as Aspergillus can be provided with foreign or natural coding regions associated with sequences of natural or foreign activators and optionally signal peptide sequences which can be used to control expression and / or the secretion of proteins encoded by these coding regions.

Injectable aqueous implant formulation containing ascorbic acid

formulação de implante aquosa injetável que contém ácido ascórbico.a presente invenção refere-se a uma formulação de implante aquosa injetável para uso na regeneração de tecido oral que foi esterilizada através de irradiação de raios gama ou raios x e pode ser extrudada através de um sistema de estreitamento e uma cânula de calibre 18 (0,838 mm de diâmetro interno) de 25,4 mm de comprimento com um força não superior a 60 n que compreende 25-45 % p/p de uma mistura de partículas de hidroxiapatita nanocristalina derivadas de osso natural que têm um tamanho de 50 a 200 µm, conforme determinado através de peneiramento, e fragmentos de material de colágeno fibroso naturalmente reticulado que passam através de uma peneira de 0,5 mm, em que a proporção p/p de hidroxiapatita nanocristalina para colágeno é a partir de 1,8 a 4,5, a qual contém pelo menos 0,05 % (p/p) de ácido ascórbico, e um processo para preparar a formulação de implante aquosa injetável acima. aqueous injectable implant formulation containing ascorbic acid. The present invention relates to an aqueous injectable implant formulation for use in the regeneration of oral tissue that has been sterilized by gamma-ray or x-ray irradiation and can be extruded through a system of and an 18 gauge cannula (0.838 mm internal diameter) 25.4 mm in length with a force not exceeding 60 n comprising 25-45 % w/w of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone which have a size of 50 to 200 µm, as determined through sieving, and fragments of naturally cross-linked fibrous collagen material passing through a 0.5 mm sieve, where the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 1.8 to 4.5, which contains at least 0.05% (w/w) ascorbic acid, and a process for preparing the above injectable aqueous implant formulation.

TRANSFORMATION SYSTEM

Transformants of Aspergillus niger and related Aspergilli, containing foreign DNA conferring modified properties of expression thereon, are prepared by use of a DNA vector which contains a selectable marker which is capable of incorporation into the DNA of the host A. niger cells, but which is not to be found in the A. niger cells prior to this transformation. The vector also contains other foreign DNA to be incorporated into the A. niger, for modified expression. The process suitably uses mutants of A. niger as hosts, the mutants lacking the selectable marker as compared with wild-type A. niger, and conducts the transformation on spheroplasts of A. niger.

METHOD FOR THE DIAGNOSIS AND THERAPY OF SCHIZOPHRENIA

Use of a Dry Implant Composition for the Preparation of an Injectable Aqueous Implant Formulation

Una formulación de implante acuoso inyectable para uso en la regeneración de tejido oral que puede extrudirse a través de un sistema de ahusamiento y una cánula de calibre 18 (0.838 mm de diámetro interior) de 25.4 mm de largo con una fuerza que no exceda los 60 N, que comprende 25-45 % p/p de una composición de implante seca que consiste esencialmente en una mezcla de partículas de hidroxiapatita nanocristalina derivadas de hueso natural que tienen un tamaño de 50 a 200 μm y fragmentos de material de colágeno fibroso entrecruzado de manera natural que pasan a través de un tamiz de 0.5 mm, por lo que la proporción p/p de hidroxiapatita nanocristalina a colágeno es de 1.8 a 4.5, rehidratada y mezclada homogéneamente con agua estéril o una solución salina isotónica estéril.

Methods and apparatus for data analysis

A method and apparatus for data analysis according to various aspects of the present invention is configured to automatically select one or more outlier identification algorithms for identifying statistical outliers in test data for components.

Promotors of filamentous fungi and use thereof

Novel vectors for use in filamentous fungi such as Aspergillus sp. in particular, whereby protein coding regions may be inserted therein to achieve expression or expression followed by secretion of the coded protein from the host. Signal peptide sequences and promoter sequences valuable for this purpose are disclosed as are expression vectors containing coding regions native or foreign to the fungal host. In accordance with the invention, a filamentous fungus such as Aspergillus may be provided with foreign or natural coding regions associated with foreign or natural promoter sequences and optionally signal peptide sequences which can be used to control the expression and/or secretion of the proteins encoded by these coding regions.

Dried implant composition and injectable aqueous implant formulation

The invention relates to: - A dried implant composition consisting essentially of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 µm and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of hydroxyapatite to collagen is from 1.8 to 4.5; - the use of that dried implant composition for preparing an injectable aqueous implant formulation for use in oral tissue regeneration that is extrudable through a tapering system and a gauge 18 (0.838 mm inner diameter) 25.4 mm long cannula; - an injectable aqueous implant formulation for use in oral tissue regeneration, wherein the injectable aqueous implant formulation is obtainable by rehydration and homogeneous mixing of 25-45 w/w % of the above dried implant composition with sterile water or a sterile isotonic saline solution, which can be extruded through a tapering system and an 8 gauge (0.838 mm inner diameter) 25.4 mm long cannula with a force not exceeding 60 N; - a process for preparing the above injectable aqueous implant formulation comprising rehydrating and homogeneously mixing 25-45 w/w % of a 20 dried implant composition as defined above in sterile water or a sterile isotonic saline solution; - a kit for preparing the above injectable aqueous implant formulation for use in oral tissue regeneration, which comprises: - a syringe equipped with a mixing device which contains a dried implant 2 composition as defined above, a tapering system and a gauge 18 (0.838 mm inner diameter) 25.4 mm long cannula; - a container filled with an appropriate amount of sterile water or a sterile isotonic solution.

Methods for diagnosing and treating schizophrenia

The genes encoding SCYA2, GADD45B, S100A8, CDKN1A, IL1RL1, TGM2, MAFF, SERPINA3, GRO1, CD14, KIAA1075, CHI3L1, SERPINH1, MT1X, KIAA0620, TIMP1, NUMA1, DDIT3 and TOB2, are upregulated in the anterior cingulate of schizophrenic patients compared to normal patients and as such are useful drug targets for schizophrenia. Methods of screening, diagnosing and treating schizophrenia based on these genes are provided. Transgenic nonhuman animals having increased copy number or increased expression levels of these genes are also provided. The transgenic nonhuman animals are used in methods for screening for potential therapeutic agents.

Methods and apparatus for data analysis

A method and apparatus for data analysis according to various aspects of the present invention is configured to automatically identify a characteristic of a fabrication process for components based on test data for the components.

Dried implant composition and injectable aqueous implant formulation

The invention relates to: An injectable aqueous implant formulation for use in oral tissue regeneration which can be extruded through a tapering system and an (18) gauge (0.838 mm inner diameter) (25.4) mm long cannula with a force not exceeding (60) N, which comprises (25-45) w/w % of a dried implant composition consisting essentially of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of (50) to (200) µm and fragments of naturally crosslinked fibrouscollagen material that pass through a (0.5) mm sieve, whereby the w/w ratio of nanocrystalline hydroxyapatite to collagen is from (1.8) to (4.5), rehydrated and homogeneously mixed with sterile water or a sterile isotonic saline solution; -aprocess for preparing the aboveinjectable aqueous implant formulation comprising rehydrating and homogeneously mixing (25-45) w/w % of a dried implant composition as defined abovein sterile water or a sterile isotonic saline solution; - a kit for preparing the above injectable aqueous implant formulation for use in oral tissue regeneration, which comprises: - a syringe equipped with a mixing device which contains a dried implant composition as defined above, a tapering system and a gauge (18) (0.838 mm inner diameter) (25.4) mm long cannula - a container filled with an appropriate amount of sterile water or a sterile isotonic solution.

Injectable aqueous implant formulation containing ascorbic acid

The invention relates to: - An injectable aqueous implant formulation for use in oral tissue regeneration which has been sterilized by gamma-ray or X-ray- irradiation and can be extruded through a tapering system and an 18 gauge (0.838 mm inner diameter) 25.4 mm long cannula with a force not exceeding 60 N, which comprises 25-45 w/w % of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 1..tm as determined by sieving and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 1.8 to 4.5, which contains at least 0.05 % (w/w) ascorbic acid, and - a process for preparing the above injectable aqueous implant formulation

Dried implant composition and injectable aqueous implant formulation

The invention relates to: - A dried implant composition consisting essentially of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 µm and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of hydroxyapatite to collagen is from 1.8 to 4.5; - the use of that dried implant composition for preparing an injectable aqueous implant formulation for use in oral tissue regeneration that is extrudable through a tapering system and a gauge 18 (0.838 mm inner diameter) 25.4 mm long cannula; - an injectable aqueous implant formulation for use in oral tissue regeneration, wherein the injectable aqueous implant formulation is obtainable by rehydration and homogeneous mixing of 25-45 w/w % of the above dried implant composition with sterile water or a sterile isotonic saline solution, which can be extruded through a tapering system and an 8 gauge (0.838 mm inner diameter) 25.4 mm long cannula with a force not exceeding 60 N; - a process for preparing the above injectable aqueous implant formulation comprising rehydrating and homogeneously mixing 25-45 w/w % of a 20 dried implant composition as defined above in sterile water or a sterile isotonic saline solution; - a kit for preparing the above injectable aqueous implant formulation for use in oral tissue regeneration, which comprises: - a syringe equipped with a mixing device which contains a dried implant 2 composition as defined above, a tapering system and a gauge 18 (0.838 mm inner diameter) 25.4 mm long cannula; - a container filled with an appropriate amount of sterile water or a sterile isotonic solution.

Focus statistics

Controlling the focus of a camera using focus statistics

Apparatus for controlling the focus of a camera arranged to capture a sequence of frames, includes an image processor configured to: form an image characteristic for a plurality of blocks of a first frame, each block comprising one or more pixels of the first frame; and calculate an image parameter for each block by combining the image characteristics of blocks lying within a predefined zone relative to that block; and a focus controller configured to derive a measure of focus for a selected frame area of the first frame by identifying a set of blocks whose respective predefined zones, when combined, substantially represent the selected frame area, and forming a measure of focus for the selected frame area by so combining the image parameters of the set of blocks; wherein the focus controller is configured to generate a signal for controlling camera focus in dependence on the measure of focus formed for the selected frame area of the first frame.

Controlling the focus of a camera using focus statistics

Apparatus for controlling the focus of a camera arranged to capture a sequence of frames, includes an image processor configured to: form an image characteristic for a plurality of blocks of a first frame, each block comprising one or more pixels of the first frame; and calculate an image parameter for each block by combining the image characteristics of blocks lying within a predefined zone relative to that block; and a focus controller configured to derive a measure of focus for a selected frame area of the first frame by identifying a set of blocks whose respective predefined zones, when combined, substantially represent the selected frame area, and forming a measure of focus for the selected frame area by so combining the image parameters of the set of blocks; wherein the focus controller is configured to generate a signal for controlling camera focus in dependence on the measure of focus formed for the selected frame area of the first frame.

Controlling the focus of a camera using focus statistics

Apparatus for controlling the focus of a camera arranged to capture a sequence of frames, includes an image processor configured to: form an image characteristic for a plurality of blocks of a first frame, each block comprising one or more pixels of the first frame; and calculate an image parameter for each block by combining the image characteristics of blocks lying within a predefined zone relative to that block; and a focus controller configured to derive a measure of focus for a selected frame area of the first frame by identifying a set of blocks whose respective predefined zones, when combined, substantially represent the selected frame area, and forming a measure of focus for the selected frame area by so combining the image parameters of the set of blocks; wherein the focus controller is configured to generate a signal for controlling camera focus in dependence on the measure of focus formed for the selected frame area of the first frame.

Verwendung des glucoamylasepromotors aus apergillus

Verfahren zur Befestigung einer Vielzahl von Bremsklötzen

2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof

2-cyanopyrrolopyrimidines and pharmaceutical uses thereof

The invention relates to pyrrolo pyrimidines of formula (I), wherein Y represents -(CH2)t-O- or -(CH2)r-S-, p is 1 or 2, r is 1, 2 or 3, t is 1, 2 or 3, or Y is -(CH2)j- or -CH=CH-, j is 1 or 2; p is 1 or 2, or Y is -(CH2)f-, f is 1 or 2, p is 1, and the further radicals and symbols have the meaning as defined herein; their preparation, their use as pharmaceuticals, pharmaceutical compositions containing them, the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment of neuropathic pain and to a method for the treatment of such a disease in animals, especially in humans.

Methods for diagnosing and treating schizophrenia

The genes encoding SCYA2, GADD45B, S100A8, CDKN1A, IL1RL1, TGM2, MAFF, SERPINA3, GRO1, CD14, KIAA1075, CHI3L1, SERPINH1, MT1X, KIAA0620, TIMP1, NUMA1, DDIT3 and TOB2, are upregulated in the anterior cingulate of schizophrenic patients compared to normal patients and as such are useful drug targets for schizophrenia. Methods of screening, diagnosing and treating schizophrenia based on these genes are provided. Transgenic nonhuman animals having increased copy number or increased expression levels of these genes are also provided. The transgenic nonhuman animals are used in methods for screening for potential therapeutic agents.

Use of mob-5 in pain

The invention discloses Mob-5 as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and/or ameliorate chronic pain and pharmaceutical compositions therefor comprising modulators with inhibitory or stimulatory effect on Mob-5 activity and/or Mob-5 gene expression. The invention also relates to a method to identify compounds with therapeutic usefulness to treat chronic pain, comprising identifying compounds that can inhibit or stimulate Mob-5 activity and/or gene expression which can also reverse the pathological effects of chronic pain in vivo.

Compositions comprising mmp7 modulators for the treatment of chronic pain

Compositions comprising mmp7 modulators for the treatment of chronic pain

The invention discloses MMP7 as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and/or ameliorate chronic pain and pharmaceutical compositions therefor comprising modulators with inhibitory effect on MMP7 enzyme activity and/or MMP7 gene expression. The invention also relates to a method to identify compounds with therapeutic usefulness to treat chronic pain, comprising identifying compounds that can inhibit MMP7 activity and/or gene expression which can also reverse the pathological effects of chronic pain in vivo.